Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis
Objectives A previous single‐country pilot study indicated serum anti‐GM2 and anti‐GA1 anti‐glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort. Materials and Methods Sera from 1...
Gespeichert in:
| Veröffentlicht in: | Journal of small animal practice 2022-02, Vol.63 (2), p.104-112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 2 |
| container_start_page | 104 |
| container_title | Journal of small animal practice |
| container_volume | 63 |
| creator | Halstead, S. K. Gourlay, D. S. Penderis, J. Bianchi, E. Dondi, M. Wessmann, A. Musteata, M. Le Chevoir, M. Martinez‐Anton, L. Bhatti, S. F. M. Volk, H. Mateo, I. Tipold, A. Ives, E. Pakozdy, A. Gutierrez‐Quintana, R. Brocal, J. Whitehead, Z. Granger, N. Pazzi, P. Harcourt‐Brown, T. José‐López, R. Rupp, S. Schenk, H. C. Smith, P. Gandini, G. Menchetti, M. Mortera‐Balsa, V. Rusbridge, C. Tauro, A. Cozzi, F. Deutschland, M. Tirrito, F. Freeman, P. Lowrie, M. Jackson, M. R. Willison, H. J. Rupp, A. |
| description | Objectives
A previous single‐country pilot study indicated serum anti‐GM2 and anti‐GA1 anti‐glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort.
Materials and Methods
Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti‐glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti‐glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis.
Results
Anti‐GM2 anti‐glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti‐GalNAc‐GD1a anti‐glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti‐glycolipid antibodies were frequently present concomitantly. Anti‐GA1 anti‐glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti‐GM2 and anti‐GalNAc‐GD1a anti‐glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti‐GalNAc‐GD1a anti‐glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87).
Clinical Significance
Anti‐GM2 and anti‐GalNAc‐GD1a immunoglobulin G anti‐glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis. |
| doi_str_mv | 10.1111/jsap.13439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2599078321</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2599078321</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3939-ab07878b5ea0359f10bc79a6d47353fdb8f4e8a9957da3d4daa039b31ca19d2a3</originalsourceid><addsrcrecordid>eNp9kUtOwzAQhi0EglLYcAAUiQ1CCviR1PGyKlBAvCRgbU1sB7kkcbEboe44AmfkJLgtsGDBbGZG_vTPeH6E9gg-JjFOJgGmx4RlTKyhHuFZkeYF5euohzGlaZYTvIW2Q5jEdpBxvIm2WMYFGeS0h5oH47smgXZmP98_xjc0lvq3hfp2qBbFKYHk8nm8fCidtiYk4E1SWteAfzE-JJXzCahuZhIFrW1NMnX13IO2qqtdazpvZzbsoI0K6mB2v3MfPZ2fPY4u0uu78eVoeJ0qJphIocS84EWZG8AsFxXBpeICBjrjLGeVLosqMwUIkXMNTGcaIidKRhQQoSmwPjpc6U69e-1MmMnGBmXqGlrjuiBpLkQcwSiJ6MEfdOI638btJB3QOI_E-0XqaEUp70LwppJTb-PX55JguTBBLkyQSxMivP8t2ZWN0b_oz9UjQFbAm63N_B8pefUwvF-JfgHsppRs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2627351510</pqid></control><display><type>article</type><title>Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Halstead, S. K. ; Gourlay, D. S. ; Penderis, J. ; Bianchi, E. ; Dondi, M. ; Wessmann, A. ; Musteata, M. ; Le Chevoir, M. ; Martinez‐Anton, L. ; Bhatti, S. F. M. ; Volk, H. ; Mateo, I. ; Tipold, A. ; Ives, E. ; Pakozdy, A. ; Gutierrez‐Quintana, R. ; Brocal, J. ; Whitehead, Z. ; Granger, N. ; Pazzi, P. ; Harcourt‐Brown, T. ; José‐López, R. ; Rupp, S. ; Schenk, H. C. ; Smith, P. ; Gandini, G. ; Menchetti, M. ; Mortera‐Balsa, V. ; Rusbridge, C. ; Tauro, A. ; Cozzi, F. ; Deutschland, M. ; Tirrito, F. ; Freeman, P. ; Lowrie, M. ; Jackson, M. R. ; Willison, H. J. ; Rupp, A.</creator><creatorcontrib>Halstead, S. K. ; Gourlay, D. S. ; Penderis, J. ; Bianchi, E. ; Dondi, M. ; Wessmann, A. ; Musteata, M. ; Le Chevoir, M. ; Martinez‐Anton, L. ; Bhatti, S. F. M. ; Volk, H. ; Mateo, I. ; Tipold, A. ; Ives, E. ; Pakozdy, A. ; Gutierrez‐Quintana, R. ; Brocal, J. ; Whitehead, Z. ; Granger, N. ; Pazzi, P. ; Harcourt‐Brown, T. ; José‐López, R. ; Rupp, S. ; Schenk, H. C. ; Smith, P. ; Gandini, G. ; Menchetti, M. ; Mortera‐Balsa, V. ; Rusbridge, C. ; Tauro, A. ; Cozzi, F. ; Deutschland, M. ; Tirrito, F. ; Freeman, P. ; Lowrie, M. ; Jackson, M. R. ; Willison, H. J. ; Rupp, A.</creatorcontrib><description>Objectives
A previous single‐country pilot study indicated serum anti‐GM2 and anti‐GA1 anti‐glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort.
Materials and Methods
Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti‐glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti‐glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis.
Results
Anti‐GM2 anti‐glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti‐GalNAc‐GD1a anti‐glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti‐glycolipid antibodies were frequently present concomitantly. Anti‐GA1 anti‐glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti‐GM2 and anti‐GalNAc‐GD1a anti‐glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti‐GalNAc‐GD1a anti‐glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87).
Clinical Significance
Anti‐GM2 and anti‐GalNAc‐GD1a immunoglobulin G anti‐glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.</description><identifier>ISSN: 0022-4510</identifier><identifier>EISSN: 1748-5827</identifier><identifier>DOI: 10.1111/jsap.13439</identifier><identifier>PMID: 34791652</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Antibodies ; Biomarkers ; Confidence intervals ; Cranial nerves ; Dog Diseases - diagnosis ; Dogs ; Female ; G(M2) Ganglioside ; Humans ; Immunoglobulin G ; Immunoglobulins ; Male ; Neuromuscular diseases ; Peripheral nerves ; Pilot Projects ; Polyradiculoneuritis ; Polyradiculoneuropathy - diagnosis ; Polyradiculoneuropathy - veterinary</subject><ispartof>Journal of small animal practice, 2022-02, Vol.63 (2), p.104-112</ispartof><rights>2021 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association</rights><rights>2021 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3939-ab07878b5ea0359f10bc79a6d47353fdb8f4e8a9957da3d4daa039b31ca19d2a3</citedby><cites>FETCH-LOGICAL-c3939-ab07878b5ea0359f10bc79a6d47353fdb8f4e8a9957da3d4daa039b31ca19d2a3</cites><orcidid>0000-0001-9247-7110 ; 0000-0002-3366-2110 ; 0000-0001-6326-5573 ; 0000-0003-0606-7831 ; 0000-0002-5160-8898 ; 0000-0002-9413-0054</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjsap.13439$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjsap.13439$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34791652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Halstead, S. K.</creatorcontrib><creatorcontrib>Gourlay, D. S.</creatorcontrib><creatorcontrib>Penderis, J.</creatorcontrib><creatorcontrib>Bianchi, E.</creatorcontrib><creatorcontrib>Dondi, M.</creatorcontrib><creatorcontrib>Wessmann, A.</creatorcontrib><creatorcontrib>Musteata, M.</creatorcontrib><creatorcontrib>Le Chevoir, M.</creatorcontrib><creatorcontrib>Martinez‐Anton, L.</creatorcontrib><creatorcontrib>Bhatti, S. F. M.</creatorcontrib><creatorcontrib>Volk, H.</creatorcontrib><creatorcontrib>Mateo, I.</creatorcontrib><creatorcontrib>Tipold, A.</creatorcontrib><creatorcontrib>Ives, E.</creatorcontrib><creatorcontrib>Pakozdy, A.</creatorcontrib><creatorcontrib>Gutierrez‐Quintana, R.</creatorcontrib><creatorcontrib>Brocal, J.</creatorcontrib><creatorcontrib>Whitehead, Z.</creatorcontrib><creatorcontrib>Granger, N.</creatorcontrib><creatorcontrib>Pazzi, P.</creatorcontrib><creatorcontrib>Harcourt‐Brown, T.</creatorcontrib><creatorcontrib>José‐López, R.</creatorcontrib><creatorcontrib>Rupp, S.</creatorcontrib><creatorcontrib>Schenk, H. C.</creatorcontrib><creatorcontrib>Smith, P.</creatorcontrib><creatorcontrib>Gandini, G.</creatorcontrib><creatorcontrib>Menchetti, M.</creatorcontrib><creatorcontrib>Mortera‐Balsa, V.</creatorcontrib><creatorcontrib>Rusbridge, C.</creatorcontrib><creatorcontrib>Tauro, A.</creatorcontrib><creatorcontrib>Cozzi, F.</creatorcontrib><creatorcontrib>Deutschland, M.</creatorcontrib><creatorcontrib>Tirrito, F.</creatorcontrib><creatorcontrib>Freeman, P.</creatorcontrib><creatorcontrib>Lowrie, M.</creatorcontrib><creatorcontrib>Jackson, M. R.</creatorcontrib><creatorcontrib>Willison, H. J.</creatorcontrib><creatorcontrib>Rupp, A.</creatorcontrib><title>Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis</title><title>Journal of small animal practice</title><addtitle>J Small Anim Pract</addtitle><description>Objectives
A previous single‐country pilot study indicated serum anti‐GM2 and anti‐GA1 anti‐glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort.
Materials and Methods
Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti‐glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti‐glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis.
Results
Anti‐GM2 anti‐glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti‐GalNAc‐GD1a anti‐glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti‐glycolipid antibodies were frequently present concomitantly. Anti‐GA1 anti‐glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti‐GM2 and anti‐GalNAc‐GD1a anti‐glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti‐GalNAc‐GD1a anti‐glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87).
Clinical Significance
Anti‐GM2 and anti‐GalNAc‐GD1a immunoglobulin G anti‐glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Biomarkers</subject><subject>Confidence intervals</subject><subject>Cranial nerves</subject><subject>Dog Diseases - diagnosis</subject><subject>Dogs</subject><subject>Female</subject><subject>G(M2) Ganglioside</subject><subject>Humans</subject><subject>Immunoglobulin G</subject><subject>Immunoglobulins</subject><subject>Male</subject><subject>Neuromuscular diseases</subject><subject>Peripheral nerves</subject><subject>Pilot Projects</subject><subject>Polyradiculoneuritis</subject><subject>Polyradiculoneuropathy - diagnosis</subject><subject>Polyradiculoneuropathy - veterinary</subject><issn>0022-4510</issn><issn>1748-5827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kUtOwzAQhi0EglLYcAAUiQ1CCviR1PGyKlBAvCRgbU1sB7kkcbEboe44AmfkJLgtsGDBbGZG_vTPeH6E9gg-JjFOJgGmx4RlTKyhHuFZkeYF5euohzGlaZYTvIW2Q5jEdpBxvIm2WMYFGeS0h5oH47smgXZmP98_xjc0lvq3hfp2qBbFKYHk8nm8fCidtiYk4E1SWteAfzE-JJXzCahuZhIFrW1NMnX13IO2qqtdazpvZzbsoI0K6mB2v3MfPZ2fPY4u0uu78eVoeJ0qJphIocS84EWZG8AsFxXBpeICBjrjLGeVLosqMwUIkXMNTGcaIidKRhQQoSmwPjpc6U69e-1MmMnGBmXqGlrjuiBpLkQcwSiJ6MEfdOI638btJB3QOI_E-0XqaEUp70LwppJTb-PX55JguTBBLkyQSxMivP8t2ZWN0b_oz9UjQFbAm63N_B8pefUwvF-JfgHsppRs</recordid><startdate>202202</startdate><enddate>202202</enddate><creator>Halstead, S. K.</creator><creator>Gourlay, D. S.</creator><creator>Penderis, J.</creator><creator>Bianchi, E.</creator><creator>Dondi, M.</creator><creator>Wessmann, A.</creator><creator>Musteata, M.</creator><creator>Le Chevoir, M.</creator><creator>Martinez‐Anton, L.</creator><creator>Bhatti, S. F. M.</creator><creator>Volk, H.</creator><creator>Mateo, I.</creator><creator>Tipold, A.</creator><creator>Ives, E.</creator><creator>Pakozdy, A.</creator><creator>Gutierrez‐Quintana, R.</creator><creator>Brocal, J.</creator><creator>Whitehead, Z.</creator><creator>Granger, N.</creator><creator>Pazzi, P.</creator><creator>Harcourt‐Brown, T.</creator><creator>José‐López, R.</creator><creator>Rupp, S.</creator><creator>Schenk, H. C.</creator><creator>Smith, P.</creator><creator>Gandini, G.</creator><creator>Menchetti, M.</creator><creator>Mortera‐Balsa, V.</creator><creator>Rusbridge, C.</creator><creator>Tauro, A.</creator><creator>Cozzi, F.</creator><creator>Deutschland, M.</creator><creator>Tirrito, F.</creator><creator>Freeman, P.</creator><creator>Lowrie, M.</creator><creator>Jackson, M. R.</creator><creator>Willison, H. J.</creator><creator>Rupp, A.</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9247-7110</orcidid><orcidid>https://orcid.org/0000-0002-3366-2110</orcidid><orcidid>https://orcid.org/0000-0001-6326-5573</orcidid><orcidid>https://orcid.org/0000-0003-0606-7831</orcidid><orcidid>https://orcid.org/0000-0002-5160-8898</orcidid><orcidid>https://orcid.org/0000-0002-9413-0054</orcidid></search><sort><creationdate>202202</creationdate><title>Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis</title><author>Halstead, S. K. ; Gourlay, D. S. ; Penderis, J. ; Bianchi, E. ; Dondi, M. ; Wessmann, A. ; Musteata, M. ; Le Chevoir, M. ; Martinez‐Anton, L. ; Bhatti, S. F. M. ; Volk, H. ; Mateo, I. ; Tipold, A. ; Ives, E. ; Pakozdy, A. ; Gutierrez‐Quintana, R. ; Brocal, J. ; Whitehead, Z. ; Granger, N. ; Pazzi, P. ; Harcourt‐Brown, T. ; José‐López, R. ; Rupp, S. ; Schenk, H. C. ; Smith, P. ; Gandini, G. ; Menchetti, M. ; Mortera‐Balsa, V. ; Rusbridge, C. ; Tauro, A. ; Cozzi, F. ; Deutschland, M. ; Tirrito, F. ; Freeman, P. ; Lowrie, M. ; Jackson, M. R. ; Willison, H. J. ; Rupp, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3939-ab07878b5ea0359f10bc79a6d47353fdb8f4e8a9957da3d4daa039b31ca19d2a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Biomarkers</topic><topic>Confidence intervals</topic><topic>Cranial nerves</topic><topic>Dog Diseases - diagnosis</topic><topic>Dogs</topic><topic>Female</topic><topic>G(M2) Ganglioside</topic><topic>Humans</topic><topic>Immunoglobulin G</topic><topic>Immunoglobulins</topic><topic>Male</topic><topic>Neuromuscular diseases</topic><topic>Peripheral nerves</topic><topic>Pilot Projects</topic><topic>Polyradiculoneuritis</topic><topic>Polyradiculoneuropathy - diagnosis</topic><topic>Polyradiculoneuropathy - veterinary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Halstead, S. K.</creatorcontrib><creatorcontrib>Gourlay, D. S.</creatorcontrib><creatorcontrib>Penderis, J.</creatorcontrib><creatorcontrib>Bianchi, E.</creatorcontrib><creatorcontrib>Dondi, M.</creatorcontrib><creatorcontrib>Wessmann, A.</creatorcontrib><creatorcontrib>Musteata, M.</creatorcontrib><creatorcontrib>Le Chevoir, M.</creatorcontrib><creatorcontrib>Martinez‐Anton, L.</creatorcontrib><creatorcontrib>Bhatti, S. F. M.</creatorcontrib><creatorcontrib>Volk, H.</creatorcontrib><creatorcontrib>Mateo, I.</creatorcontrib><creatorcontrib>Tipold, A.</creatorcontrib><creatorcontrib>Ives, E.</creatorcontrib><creatorcontrib>Pakozdy, A.</creatorcontrib><creatorcontrib>Gutierrez‐Quintana, R.</creatorcontrib><creatorcontrib>Brocal, J.</creatorcontrib><creatorcontrib>Whitehead, Z.</creatorcontrib><creatorcontrib>Granger, N.</creatorcontrib><creatorcontrib>Pazzi, P.</creatorcontrib><creatorcontrib>Harcourt‐Brown, T.</creatorcontrib><creatorcontrib>José‐López, R.</creatorcontrib><creatorcontrib>Rupp, S.</creatorcontrib><creatorcontrib>Schenk, H. C.</creatorcontrib><creatorcontrib>Smith, P.</creatorcontrib><creatorcontrib>Gandini, G.</creatorcontrib><creatorcontrib>Menchetti, M.</creatorcontrib><creatorcontrib>Mortera‐Balsa, V.</creatorcontrib><creatorcontrib>Rusbridge, C.</creatorcontrib><creatorcontrib>Tauro, A.</creatorcontrib><creatorcontrib>Cozzi, F.</creatorcontrib><creatorcontrib>Deutschland, M.</creatorcontrib><creatorcontrib>Tirrito, F.</creatorcontrib><creatorcontrib>Freeman, P.</creatorcontrib><creatorcontrib>Lowrie, M.</creatorcontrib><creatorcontrib>Jackson, M. R.</creatorcontrib><creatorcontrib>Willison, H. J.</creatorcontrib><creatorcontrib>Rupp, A.</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of small animal practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Halstead, S. K.</au><au>Gourlay, D. S.</au><au>Penderis, J.</au><au>Bianchi, E.</au><au>Dondi, M.</au><au>Wessmann, A.</au><au>Musteata, M.</au><au>Le Chevoir, M.</au><au>Martinez‐Anton, L.</au><au>Bhatti, S. F. M.</au><au>Volk, H.</au><au>Mateo, I.</au><au>Tipold, A.</au><au>Ives, E.</au><au>Pakozdy, A.</au><au>Gutierrez‐Quintana, R.</au><au>Brocal, J.</au><au>Whitehead, Z.</au><au>Granger, N.</au><au>Pazzi, P.</au><au>Harcourt‐Brown, T.</au><au>José‐López, R.</au><au>Rupp, S.</au><au>Schenk, H. C.</au><au>Smith, P.</au><au>Gandini, G.</au><au>Menchetti, M.</au><au>Mortera‐Balsa, V.</au><au>Rusbridge, C.</au><au>Tauro, A.</au><au>Cozzi, F.</au><au>Deutschland, M.</au><au>Tirrito, F.</au><au>Freeman, P.</au><au>Lowrie, M.</au><au>Jackson, M. R.</au><au>Willison, H. J.</au><au>Rupp, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis</atitle><jtitle>Journal of small animal practice</jtitle><addtitle>J Small Anim Pract</addtitle><date>2022-02</date><risdate>2022</risdate><volume>63</volume><issue>2</issue><spage>104</spage><epage>112</epage><pages>104-112</pages><issn>0022-4510</issn><eissn>1748-5827</eissn><abstract>Objectives
A previous single‐country pilot study indicated serum anti‐GM2 and anti‐GA1 anti‐glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort.
Materials and Methods
Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti‐glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti‐glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis.
Results
Anti‐GM2 anti‐glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti‐GalNAc‐GD1a anti‐glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti‐glycolipid antibodies were frequently present concomitantly. Anti‐GA1 anti‐glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti‐GM2 and anti‐GalNAc‐GD1a anti‐glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti‐GalNAc‐GD1a anti‐glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87).
Clinical Significance
Anti‐GM2 and anti‐GalNAc‐GD1a immunoglobulin G anti‐glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>34791652</pmid><doi>10.1111/jsap.13439</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9247-7110</orcidid><orcidid>https://orcid.org/0000-0002-3366-2110</orcidid><orcidid>https://orcid.org/0000-0001-6326-5573</orcidid><orcidid>https://orcid.org/0000-0003-0606-7831</orcidid><orcidid>https://orcid.org/0000-0002-5160-8898</orcidid><orcidid>https://orcid.org/0000-0002-9413-0054</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-4510 |
| ispartof | Journal of small animal practice, 2022-02, Vol.63 (2), p.104-112 |
| issn | 0022-4510 1748-5827 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2599078321 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Antibodies Biomarkers Confidence intervals Cranial nerves Dog Diseases - diagnosis Dogs Female G(M2) Ganglioside Humans Immunoglobulin G Immunoglobulins Male Neuromuscular diseases Peripheral nerves Pilot Projects Polyradiculoneuritis Polyradiculoneuropathy - diagnosis Polyradiculoneuropathy - veterinary |
| title | Serum anti‐GM2 and anti‐GalNAc‐GD1a IgG antibodies are biomarkers for acute canine polyradiculoneuritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T08%3A45%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20anti%E2%80%90GM2%20and%20anti%E2%80%90GalNAc%E2%80%90GD1a%20IgG%20antibodies%20are%20biomarkers%20for%20acute%20canine%20polyradiculoneuritis&rft.jtitle=Journal%20of%20small%20animal%20practice&rft.au=Halstead,%20S.%20K.&rft.date=2022-02&rft.volume=63&rft.issue=2&rft.spage=104&rft.epage=112&rft.pages=104-112&rft.issn=0022-4510&rft.eissn=1748-5827&rft_id=info:doi/10.1111/jsap.13439&rft_dat=%3Cproquest_cross%3E2599078321%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2627351510&rft_id=info:pmid/34791652&rfr_iscdi=true |